187 related articles for article (PubMed ID: 7685990)
1. Evidence of a direct relationship between the increase in the in vitro passage number of human non-small-cell-lung cancer primocultures and their chemosensitivity.
Kruczynski A; Kiss R
Anticancer Res; 1993; 13(2):507-13. PubMed ID: 7685990
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous evolution of nuclear size and DNA content of non-small-cell-lung cancers grafted onto nude mice.
Kruczynski A; Pauwels O; Wright M; Delsol G; Kiss R
Cytometry; 1992; 13(6):586-94. PubMed ID: 1333395
[TBL] [Abstract][Full Text] [Related]
3. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
4. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
6. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
[TBL] [Abstract][Full Text] [Related]
8. In vivo effect of pachymatismin, a new marine glycoprotein, on a human non-small-cell lung carcinoma.
Zidane M; Moré MT; Pondaven P; Jaquot C; Riou D; Roussakis C
In Vivo; 1997; 11(2):185-8. PubMed ID: 9179614
[TBL] [Abstract][Full Text] [Related]
9. [Development of new in vitro chemosensitivity test using collagen gel droplet embedded culture and its clinical usefulness].
Kobayashi H; Tanisaka K; Kondo N; Mito Y; Koezuka M; Yokouchi H; Higashiyama M; Kodama K; Doi O; Yamada M
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1933-9. PubMed ID: 7487123
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy.
Ishibashi H; Suzuki T; Suzuki S; Niikawa H; Lu L; Miki Y; Moriya T; Hayashi S; Handa M; Kondo T; Sasano H
Cancer Res; 2005 Jul; 65(14):6450-8. PubMed ID: 16024650
[TBL] [Abstract][Full Text] [Related]
11. In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis.
Tanigawa N; Kitaoka A; Yamakawa M; Tanisaka K; Kobayashi H
Anticancer Res; 1996; 16(4A):1925-30. PubMed ID: 8712722
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
14. Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides.
Olbina G; Cieslak D; Ruzdijic S; Esler C; An Z; Wang X; Hoffman R; Seifert W; Pietrzkowski Z
Anticancer Res; 1996; 16(6B):3525-30. PubMed ID: 9042216
[TBL] [Abstract][Full Text] [Related]
15. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway.
DeCicco KL; Tanaka T; Andreola F; De Luca LM
Carcinogenesis; 2004 Oct; 25(10):1805-12. PubMed ID: 15205358
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors in human lung cancer therapy.
Weinberg OK; Marquez-Garban DC; Fishbein MC; Goodglick L; Garban HJ; Dubinett SM; Pietras RJ
Cancer Res; 2005 Dec; 65(24):11287-91. PubMed ID: 16357134
[TBL] [Abstract][Full Text] [Related]
17. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.
Boven E; Winograd B; Berger DP; Dumont MP; Braakhuis BJ; Fodstad O; Langdon S; Fiebig HH
Cancer Res; 1992 Nov; 52(21):5940-7. PubMed ID: 1394220
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
Lei W; Mayotte JE; Levitt ML
Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
20. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
